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Heart failure is commonly caused by coronary disease [1]
and accounts for a substantial part of post-infarction mor-
bidity and mortality. Prevention and treatment of heart
failure is, therefore, an integral part of post-infarction
therapy.
The benefit of angiotensin-converting enzyme (ACE)
inhibitors in heart failure is well documented [2–4]. Sharpe
et al demonstrated in 1986 that post-infarction treatment
with the ACE inhibitor captopril attenuated left ventricular
(LV) remodeling [5]. The effect was more pronounced with
treatment initiated within the first 24 hours [6]. Several
large clinical trials have subsequently demonstrated a
reduction in mortality and morbidity with ACE inhibition fol-
lowing myocardial infarction [7–9]. The evidence has been
strongest following prolonged treatment (6–60 months) in
patients with LV dysfunction [10,11] or with symptomatic
heart failure [12]. In unselected patients [7,8], however,
there has been no clinical evidence to support a treatment
effect beyond 6 weeks.
The renin–angiotensin system (RAS) plays an important
role in the initiation and progression of atherosclerosis
[13]. Clinical data exists that indicates an effect of ACE
inhibitors in the prevention of myocardial infarction and
unstable angina [10,14]. The recently completed Heart
Outcome Prevention Evaluation (HOPE) trial included
patients with coronary artery disease, stroke, peripheral
vascular disease, or diabetics with additional cardiovascu-
lar risk factors. Over 50% of the patients in the HOPE
study had suffered a myocardial infarction, but none had
symptomatic heart failure [15]. In the trial, ramipril treat-
ment (lasting an average of 4.5 years) caused a significant
reduction in cardiovascular events. This supports the use
of chronic ACE-inhibitor therapy in a wider range of post-
infarction patients, independent of cardiac status.
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Abstract
Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity
and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until
recently, the effect of such treatment in patients with preserved LV function has not been known. The
results from the Heart Outcome Prevention Evaluation trial have indicated that long-term treatment with
ramipril leads to a significant reduction in cardiovascular events in patients with atherosclerotic
disease, including those with prior myocardial infarction and preserved LV function. These results
suggest that long-term angiotensin-converting enzyme inhibition should also be considered in post-
infarction patients with normal cardiac function.
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Post-infarction trials with converting enzyme
inhibitors
Post-infarction ACE-inhibitor trials may be divided into two
main categories (Table 1). In one trial, patients with acute
myocardial infarction were included consecutively, irrespec-
tive of cardiac function [7,8,16]. In the other, patients were
selected and included only if they had heart failure [12], LV
dysfunction [10,11], or a transmural anterior wall infarction
[9]. The Fourth International Study of Infarct Survival (ISIS-
4) and Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarcto Miocardico (GISSI-3), in which all post-infarc-
tion patients were randomized, demonstrated a marginal but
statistically significant mortality reduction at 5 and 6 weeks,
respectively. There has been no data showing an effect of
long-term treatment in unselected patients. Some patients
were followed-up for 6 months in the Cooperative New
Scandinavian Enalapril Survival Study (CONSENSUS II),
but this trial was terminated prematurely because, based on
an interim analysis, the chances of demonstrating a treat-
ment effect were considered unlikely.
The average duration of treatment in the Acute Infarction
Ramipril Efficacy (AIRE), the Trandolapril Cardiac Evalua-
tion (TRACE), and the Survival and Ventricular Enlarge-
ment (SAVE) trials were 15, 27, and 42 months,
respectively. A highly significant reduction in mortality was
observed during this period (Table 1). There is therefore
sufficient evidence to state that long-term ACE-inhibitor
therapy for up to 5 years provides a continuous, cumula-
tive benefit in patients with post-infarction heart failure or
LV dysfunction.
The RAS in cardiovascular disease
Neurohormonal activation in heart failure
Myocardial infarction results in ischemia and necrosis of
myocytes, causing myocardial dysfunction and a reduction
in cardiac output. This activates several compensatory
mechanisms, including neurohormonal activation, in an
effort to maintain adequate perfusion of vital organ
systems. Neurohormonal activation, primarily of the sympa-
thetic nervous system and the RAS, counteracts myocar-
dial dysfunction initially, but may eventually aggravate the
underlying pathophysiology, causing a further deterioration
of cardiac function. Results from clinical trials in patients
with heart failure have demonstrated lower mortality and
improved morbidity with converting-enzyme inhibition
[2–4], as well as with beta-blockers [17,18]. This indi-
cates that neurohormonal activation is important in the
pathophysiology of heart failure and contributes to the pro-
gression of this condition.
Autocrine and paracrine activity of the RAS
The RAS was previously conceived to be an endocrine
system regulating the circulation. It has subsequently been
demonstrated that the RAS not only has endocrine activ-
ity, but also operates as autocrine and paracrine systems,
acting at multiple sites (including cardiac, vascular, and
renal tissues) [19]. All components of the RAS, and
angiotensin II receptor subtypes 1 and 2, have been iden-
tified in cardiac tissue [20]. Markedly increased ACE
immunoreactivity has been demonstrated in human
myocytes adjacent to infarct scars [21]. The major effect
of ACE inhibition in cardiac disorders may therefore not be
Table 1
Post-infarction angiotensin converting enzyme-inhibitor trials
Unselected post-infarction patients Post-infarction patients with left ventricular dysfunction
Trial CONSENSUS  II  GISSI-3  ISIS-4 SAVE AIRE SMILE TRACE
[Reference no] [16] [8] [7] [10] [12] [9] [11]
Drug Enalapril Lisinopril Captopril Captopril Ramipril Zofenopril Trandolapril
Number of patients 6090 19,394 58,050 2231 2006 1556 1749
Target dose 20 mg × 1 10 mg × 1 50 mg × 2 50 mg × 3 5 mg × 2 30 mg × 2 4 mg × 1
Inclusion criteria AMI  AMI AMI LVEF < 40% Signs or  Anterior wall Low wall
consecutively consecutively consecutively symptoms of  AMI without motion index
heart failure thrombolytics  score
Follow-up time 1.5–6 months  6 weeks 5 weeks 24–60 months 6–30 months 6 weeks 24–50 months
(trial stopped)
Mortality reduction P: 10.2%  P: 7.1%  P: 7.7%  P: 25%  P: 23%  P: 10.6%  P : 42.3% 
T: 11.0% T: 6.3% T: 7.2% T: 20% T: 17% T: 7.1% T: 34.7%
Risk reduction  –10 % 12% 7% 19% 27% 25% 22%
(95% CI) (–29 to 7%) (1% to 21%) (1% to 13%) (3% to 32%) (11% to 40%) (–11% to 60% (9% to 33%)
Level of significance P = 0.26 P = 0.03 P = 0.02 P = 0.019 P = 0.002 P = 0.19  P = 0.001
SMILE, Survival of Myocardial Infarction Long-Term Evaluation; AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; P, placebo;
























due to inhibition of systemic angiotensin production, but
due to reduced tissue angiotensin II activity.
RAS and remodeling
The change in size, shape, and function of the
myocardium following infarction, a process termed
‘remodeling’, is modulated by angiotensin II. Necrotic
myocytes release a number of cytokines, including
transforming growth factor β1, which initiates the infiltra-
tion and activation of inflammatory cells, such as neu-
trophils, monocytes, and macrophages. Tissue
fibroblasts proliferate and transform into myofibroblasts.
The intercellular collagen is first degraded by matrix
metalloproteinases, resulting in myocyte slippage and
expansion of the infarcted area. During the later phase,
there is new collagen deposition and the formation of
scar tissue. Activated inflammatory cells as well as
myofibroblasts have abundant angiotensin II receptor
subtype 1 receptors. They also express ACE activity
and provide a local source of angiotensin II production
that is independent of systemic angiotensin II [22].
Angiotensin II, therefore, plays an important role in LV
remodeling after infarction. This has been confirmed by
clinical studies demonstrating reduced LV volumes with
ACE inhibition following infarction [6,23]. Moreover, the
process of new collagen deposition and scar formation
may, in some cases, affect distant non-infarcted
myocardium, resulting in inappropriate fibrosis and com-
bined systolic and diastolic dysfunction [24]. Reduced
angiotensin II concentrations may prevent this occur-
ring. Treatment with the ACE inhibitor enalapril has
been shown to preserve regional wall motion in the non-
infarcted region in patients with anterior wall myocardial
infarction [25]. Aldosterone is also operative in this
pathological production of fibrous tissue [26]
RAS and atherosclerosis
The RAS not only plays a role in the development of
cardiac remodeling and heart failure, but also affects
several other aspects of cardiovascular disease including
the pathogenesis of atherosclerosis. There is sufficient
evidence indicating an important role of the RAS in induc-
ing endothelial dysfunction, and the induction of inflam-
matory responses in the vessel wall [13]. Experimental
studies indicate that angiotensin II-mediated superoxide
production in vessel walls plays a crucial role in the early
stages of atherosclerosis [27]. It has been demonstrated
that human coronary atherosclerotic lesions contain
angiotensin II [28], and a study of human coronary arter-
ies indicates that ACE, and not chymase, is the major
enzyme in the production of angiotensin II in atheroscle-
rotic lesions [29]. The importance of ACE inhibitors in the
progression of coronary disease has also been demon-
strated in clinical studies. The SAVE trial demonstrated a
25% reduction in recurrent myocardial infarction [10],
and a 23% reduction in myocardial infarction and a 20%
reduction in the development of unstable angina was
observed in the Studies of Left Ventricular Dysfunction
(SOLVD) trial [14]
ACE inhibition and cardiovascular risk
reduction
The HOPE trial is the first major clinical trial in which long-
term ACE inhibition has been evaluated in patients with
coronary artery disease, without heart failure or known LV
dysfunction [15]. A total of 9297 patients with atheroscle-
rotic disease, including coronary artery disease, stroke, or
peripheral vascular disease, were included in this study.
Patients with diabetes mellitus, with at least one additional
risk factor such as hypertension, elevated levels of choles-
terol, microalbuminuria, or smoking, were also included.
There were 4892 cases among these patients who had
suffered from a prior myocardial infarction. Patients were
randomized to treatment with the ACE inhibitor ramipril
(n = 4645), or placebo (n = 4652), up to a target dose of
10 mg once daily. Results after an average of 4.5 years of
treatment demonstrated a highly significant reduction in
total mortality (16%; 95% confidence interval [CI],
5–25%), cardiovascular mortality (26%; 95% CI,
13–34%), recurrent myocardial infarction (20%; 95% CI,
10–30%), and stroke (32%; 95% CI, 16–44%). The inci-
dence of heart failure was reduced by 23% (95% CI,
13–33%). Recurrent myocardial infarction, stroke, and
cardiovascular death was reduced by 20.9% in the sub-
group of patients with prior myocardial infarction.
Implications and limitations of HOPE
The application of the results of the HOPE trial may have
substantial clinical implications. It has been suggested
that, if only one-half of the eligible patients in developed
countries and a quarter of eligible patients in developing
countries were treated with ramipril, over 1 million major
cardiovascular events would be prevented every year [30].
The results of the HOPE trial have recently been com-
pared with other post-infarction trials [31], and it has been
demonstrated that post-infarction ramipril therapy is as
cost-effective as other prophylactic treatment, such as the
use of lipid-lowering agents.
A literal interpretation of the results of the HOPE trial
would suggest that all patients following myocardial infarc-
tion should be placed on ACE inhibitors. It must be con-
sidered, however, that these results are based on post
hoc subgroup analysis, and results from such an analysis
should be interpreted with appropriate conservatism. Pub-
lished data does not provide enough detailed information
to adequately describe the cohort with prior myocardial
infarction. Eighty-five percent of these patients suffered
their infarction more than 1 year prior to inclusion. All
patients in this study were older than 55 years of age and
the results may not apply to a younger population. Data on
ejection fraction was available in less than 60% of the
Available online http://cvm.controlled-trials.com/content/2/4/151patients, and many of these patients with infarction had
co-morbid conditions such as peripheral vascular disease,
cerebrovascular disease, hypertension, and diabetes,
which may have affected the results. The HOPE trial was
performed before the use of current guidelines, which
include more sensitive troponin assays [32]. The results
may therefore not apply to all patients that are diagnosed
with myocardial infarction today. The question of whether
uncomplicated myocardial infarction itself represents an
indication for long-term ACE inhibition must, therefore, be
determined in prospective trials.
Beta-blocker therapy is indicated in most post-infarction
patients. The timing and titration of beta-blockers in com-
bination with ACE inhibitors may be a therapeutic chal-
lenge. This is an issue that needs to be addressed when
considering optimal treatment of patients after a myocar-
dial infarction.
Conclusion
Strong evidence exists suggesting that ACE-inhibitor
treatment should be initiated early and continued for years,
in patients with heart failure and/or LV dysfunction, follow-
ing myocardial infarction. Results of the HOPE trial indi-
cate that chronic treatment with ramipril should also be
considered in post-infarction patients without heart failure.
Whether the results of the HOPE trial also apply for other
ACE inhibitors or angiotensin II receptor blockers should
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